Grifols, S.a.

Grifols Worldwide Operations Limited

Salvador Grancha Gamon

Pere Ristol Debart

Juan Ignacio Jorquera Nieto

Montserrat Costa Rierola

Montserrat Miñarro Carmona

Ana Maria Ortiz Fernandez

Anna Nardi Ricart

Josep Mariá Suñe Negre

Josep Ramón Tico Grau

Josep Maria Sune Negre

Marta Massot Riera

Josep Ramon Tico Grau

Montserrat Minarro Carmona

Josep Maria Suñe Negre

Monserrat Miñarro Carmona

A process for obtaining an IgG composition involves heat treatment. This process obtains an IgG composition from an IgG solution partly purified from human plasma, in which by applying intermediate heat treatment and without using reagents to precipitate high molecular weight aggregates/polymers and/or proteins virtually total elimination of the IgG polymers generated during the process is achieved. Furthermore this process offers high productivity, lower production costs and is easy to implement in comparison with the processes of the know art. In addition to this, by using this process stability is imparted to the final product in liquid.

Process for obtaining an IgG composition through heat treatment

Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration. The invention relates to a biocompatible composition which comprises microparticles of alginic acid or its salts and an active ingredient. More particularly, the invention relates to microparticles for the encapsulation of an active ingredient to be administered intravenously to a patient who needs it. These microparticles are of a combination of size sufficient to increase the half-life or survival of the active ingredient in blood, with a low uptake in the liver and a fast cell clearance when administered intravenously.

Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration

The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography and its subsequent activation.

Therapeutic preparation of very high purity FVIIa and method for obtaining same

Growing community of inventors

Barcelona, Spain

Salvador Grancha Gamon